Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force
The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Screening for type 2 diabetes mellitus could lead to earlier identification and treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IGT), potentially resulting in improved outcomes. PURPOSE: To update the 2008 U.S. Preventive Services Task Force review on diabetes screening in adults. DATA SOURCES: Cochrane databases and MEDLINE (2007 through October 2014) and relevant studies from previous Task Force reviews. STUDY SELECTION: Randomized, controlled trials; controlled, observational studies; and systematic reviews. DATA EXTRACTION: Data were abstracted by 1 investigator and checked by a second; 2 investigators independently assessed study quality. DATA SYNTHESIS: In 2 trials, screening for diabetes was associated with no 10-year mortality benefit versus no screening (hazard ratio, 1.06 [95% CI, 0.90 to 1.25]). Sixteen trials consistently found that treatment of IFG or IGT was associated with delayed progression to diabetes. Most trials of treatment of IFG or IGT found no effects on all-cause or cardiovascular mortality, although lifestyle modification was associated with decreased risk for both outcomes after 23 years in 1 trial. For screen-detected diabetes, 1 trial found no effect of an intensive multifactorial intervention on risk for all-cause or cardiovascular mortality versus standard control. In diabetes that was not specifically screen-detected, 9 systematic reviews found that intensive glucose control did not reduce risk for all-cause or cardiovascular mortality and results for intensive blood pressure control were inconsistent. LIMITATION: The review was restricted to English-language articles, and few studies were conducted in screen-detected populations. CONCLUSION: Screening for diabetes did not improve mortality rates after 10 years of follow-up. More evidence is needed to determine the effectiveness of treatments for screen-detected diabetes. Treatment of IFG or IGT was associated with delayed progression to diabetes. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 203
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Statistical heterogeneity was assessed using the I(2) statistic (26).”
MethodReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 5×
“Chiasson et al, 2002 (51)* Knowler et al, 2002 (7)* Gernstein et al, 2006 (52)* Holman et al, 2010 (28) Ramachandran et al, 2009 (48) M-H overall (I2 = 0.0”
BackgroundInfluentialDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“…incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001 (9)* D+L overall (I2 = 77”
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“Harms of other interventions, including intensive BP-lowering and intensive multifactorial interventions, were mixed (71, 72, 81, 82).”
BackgroundAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · cited 1×
“Based on 8 studies (10, 28, 45–48, 51, 52) of glucose-lowering agents, including 3 (10, 51, 52) from the previous USPSTF review (22), the pooled odds ratio for all-cause mortality was 1.”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881 · cited 2×
“…incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001 (9)* D+L overall (I2 = 77”
InfluentialChiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600 · cited 1×
“This study had previously reported no difference in these outcomes after 20-year follow-up (39).”
ResultRay, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306 · cited 1×
“Diabetes typically develops slowly (4, 5), although microvascular disease, such as retinopathy and neuropathy, may be present at the time of diagnosis due to vascular damage during the subclinical phase (4, 6).”
BackgroundMorrison, A., Polisena, J., Husereau, D., Moulton, K., Clark, M., Fiander, M., Mierzwinski-Urban, M., Clifford, T., Hutton, B., & Rabb, D. (2012) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462312000086 · Cited by 1,257
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Schrier, R. W., Estacio, R. O., Esler, A., & Mehler, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 851
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 4×
“Meta-analysis of the effect of lifestyle interventions on incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto…”
BackgroundInfluentialLong-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Cradock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., et al. (2008) · BMJ · doi:10.1136/bmj.39474.922025.be · Cited by 760
Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.010 · Cited by 730 · cited 1×
“For rare events (incidence <1%), we calculated the Peto odds ratio (31).”
MethodLi, G., Zhang, P., Wang, J., An, Y., Gong, Q., Gregg, E. W., Yang, W., Zhang, B., Shuai, Y., Hong, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70057-9 · Cited by 684 · cited 6×
“In conclusion, screening for diabetes did not improve mortality rates after 10 years of follow-up in 2 trials (32, 33) but was found to decrease mortality rates in a lifestyle intervention study with 23 years of follow-up (38).”
BackgroundResultInfluentialEffect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males
Kosaka, K., Noda, M., & Kuzuya, T. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.06.010 · Cited by 656 · cited 1×
“Meta-analysis of the effect of lifestyle interventions on incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al,…”
BackgroundThe Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Khunti, K., Gray, L. J., Skinner, T., Carey, M. E., Realf, K., Dallosso, H., Fisher, H., Campbell, M., Heller, S., & Davies, M. J. (2012) · BMJ · doi:10.1136/bmj.e2333 · Cited by 465
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462 · cited 2×
“Mortality and cardiovascular event rates were lower than anticipated, with little difference between groups in final hemoglobin A1c and total cholesterol levels and BP (55).”
BackgroundRandom-Effects Meta-analysis of Inconsistent Effects: A Time for Change
Cornell, J. E., Mulrow, C. D., Localio, R., Stack, C. B., Meibohm, A. R., Guallar, E., & Goodman, S. N. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2886 · Cited by 453 · cited 2×
“When statistical heterogeneity was present, we performed sensitivity analyses using the profile likelihood method because the DerSimonian–Laird model results in overly narrow 95% CIs (27).”
MethodBangalore, S., Kumar, S., Lobach, I., & Messerli, F. H. (2011) · Circulation · doi:10.1161/circulationaha.110.016337 · Cited by 437 · cited 2×
“95]; I(2) = 27%) in 1 good-quality systematic review (70), but individual trials defined intensive BP control differently and some trials showed inconsistent effects (Appendix Table 4, available at www.”
BackgroundResultHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386 · cited 2×
“One of the largest and most recent reviews (60) analyzed evidence from 14 trials (n = 28 614), including several large, good-quality trials (67–69) published since the previous USPSTF report.”
BackgroundSystematic review: glucose control and cardiovascular disease in type 2 diabetes
Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., & He, J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-6-200909150-00137 · Cited by 358 · cited 1×
“In persons with diabetes not specifically screendetected, intensive glucose control was associated with increased risk for severe hypoglycemia and serious nonhypoglycemia adverse events requiring medical intervention (Appendix Table 3) (59, 60, 63, 65).”
BackgroundKawamori, R., Tajima, N., Iwamoto, Y., Kashiwagi, A., Shimamoto, K., & Kaku, K. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60222-1 · Cited by 303 · cited 2×
“Chiasson et al, 2002 (51)* DeFronzo et al, 2011 (45) Gernstein et al, 2006 (52)* Kawamori et al, 2009 (46) Holman et al, 2010 (28) Nijpels et al, 2008 (47) Ramachandran et al, 2006 (10)* Ramachandran et al, 2009 (48) M-H overall (I2 = 0.0”
BackgroundInfluentialAndrews, R., Cooper, A., Montgomery, A., Norcross, A., Peters, T., Sharp, D., Jackson, N., Fitzsimons, K., Bright, J., Coulman, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60442-x · Cited by 302
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Early detection of undiagnosed diabetes mellitus: a US perspective
Harris, M. I., & Eastman, R. C. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/1520-7560(2000)9999:9999<::aid-dmrr122>3.0.co;2-w · Cited by 287 · cited 1×
“Diabetes typically develops slowly (4, 5), although microvascular disease, such as retinopathy and neuropathy, may be present at the time of diagnosis due to vascular damage during the subclinical phase (4, 6).”
BackgroundSaito, T. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.275 · Cited by 277 · cited 1×
“…incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001 (9)* D+L overall (I2 = 77”
Zoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0959 · Cited by 256
Simmons, R. K., Echouffo-Tcheugui, J. B., Sharp, S. J., Sargeant, L. A., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61422-6 · Cited by 252
GRuttenfor the ADDITION Study Group, Lauritzen, T., Griffin, S., Borch-Johnsen, K., Wareham, N., & Wolffenbuttel, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801420 · Cited by 249 · cited 1×
“The ongoing ADDITION trial includes sites in Cambridge, the Netherlands, and Denmark on intensive versus standard treatment of screendetected diabetes; however, only the Cambridge site had a no-screening component (34).”
MethodHoward, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 241 · cited 1×
“Harms of other interventions, including intensive BP-lowering and intensive multifactorial interventions, were mixed (71, 72, 81, 82).”
BackgroundSwinburn, B. A., Metcalf, P. A., & Ley, S. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.619 · Cited by 240
Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Norris, S. L., Kansagara, D., Bougatsos, C., & Fu, R. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00008 · Cited by 228
Self-citationUusitupa, M., Peltonen, M., Lindström, J., Aunola, S., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Valle, T. T., Eriksson, J. G., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2009) · PLoS ONE · doi:10.1371/journal.pone.0005656 · Cited by 215
Mannucci, E., Monami, M., Lamanna, C., Gori, F., & Marchionni, N. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.021 · Cited by 201
Dagenais (2008) · doi:10.2337/dc07-1868 · Cited by 183
Dungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173 · cited 2×
“Three trials were rated goodquality (28, 29, 46, 49), and the remainder were fairquality.”
BackgroundPenn, L., White, M., Oldroyd, J., Walker, M., Alberti, K. G. M., & Mathers, J. C. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-342 · Cited by 153 · cited 1×
“…incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001 (9)* D+L overall (I2 = 77”
Recommendations on screening for type 2 diabetes in adults
Canadian Task Force on Preventive Health Care (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.120732 · Cited by 137
Schrier, R. W., Estacio, R. O., Mehler, P. S., & Hiatt, W. R. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0559 · Cited by 128
The Healthy Living Partnerships to Prevent Diabetes Study
Katula, J. A., Vitolins, M. Z., Morgan, T. M., Lawlor, M. S., Blackwell, C. S., Isom, S. P., Pedley, C. F., & Goff, D. C. (2013) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.12.015 · Cited by 127
Japan Diabetes Prevention Program (JDPP) Research Group the for, Sakane, N., Sato, J., Tsushita, K., Tsujii, S., Kotani, K., Tsuzaki, K., Tominaga, M., Kawazu, S., Sato, Y., et al. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-40 · Cited by 126 · cited 1×
“…incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001 (9)* D+L overall (I2 = 77”
Harris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00015 · Cited by 113
Florez, H. J., Pan, Q., Ackermann, R. T., Marrero, D. G., Barrett-Connor, E. L., Delahanty, L. M., Kriska, A. M., Saudek, C. D., Goldberg, R. B., & Rubin, R. R. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2122-5 · Cited by 110
Ramachandran, A., Snehalatha, C., Mary, S., Selvam, S., Kumar, C. K. S., Seeli, A. C., & Shetty, A. S. (2009) · Diabetologia · doi:10.1007/s00125-009-1315-x · Cited by 105 · cited 2×
“Excluding the Indian Diabetes Prevential Programme-2 trial (48), which was conducted in India among mostly male participants, eliminated much of the heterogeneity (RR, 0.”
BackgroundJanssen, P. G., Gorter, K. J., Stolk, R. P., & Rutten, G. E. (2009) · British Journal of General Practice · doi:10.3399/bjgp09x394851 · Cited by 87
Lindahl, B., Nilssön, T. K., Borch-Johnsen, K., Røder, M. E., Söderberg, S., Widman, L., Johnson, O., Hallmans, G., & Jansson, J.-H. (2009) · Scandinavian Journal of Public Health · doi:10.1177/1403494808101373 · Cited by 87 · cited 1×
“…interventions on incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001…”
Dyson, P. A., Hammersley, M. S., Morris, R. J., Holman, R. R., & Turner, R. C. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90318-8 · Cited by 73
Watanabe, M., Yamaoka, K., Yokotsuka, M., & Tango, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3209 · Cited by 69
Park, P., Simmons, R. K., Prevost, A. T., & Griffin, S. J. (2008) · BMC Public Health · doi:10.1186/1471-2458-8-350 · Cited by 68
Simmons, R. K., Rahman, M., Jakes, R. W., Yuyun, M. F., Niggebrugge, A., Hennings, S., Williams, D. R. R., Wareham, N. J., & Griffin, S. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1949-8 · Cited by 64 · cited 6×
“In conclusion, screening for diabetes did not improve mortality rates after 10 years of follow-up in 2 trials (32, 33) but was found to decrease mortality rates in a lifestyle intervention study with 23 years of follow-up (38).”
BackgroundInfluentialEfficacy of acarbose in Chinese subjects with impaired glucose tolerance
Pan, C., Gao, Y. H., Chen, J., Luo, B.-Y., Zu-zhi, F., Lu, J., Guo, X., & Cheng, H. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(03)00117-7 · Cited by 60 · cited 1×
“Meta-analysis of the effect of -glucosidase inhibitors on incidence of progression to DM. Chiasson et al, 2002 (51)* Kawamori et al, 2009 (46) Nijpels et al, 2008 (47) Pan et al, 2003 (91)† D+L overall (I2 = 67”
BackgroundBuehler, A. M., Cavalcanti, A. B., Berwanger, O., Figueiro, M., Laranjeira, L. N., Zazula, A. D., Kioshi, B., Bugano, D. G., Santucci, E., Sbruzzi, G., et al. (2013) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00308.x · Cited by 50
Ma, J., Yang, W., Fang, N.-Y., Zhu, W., & Wei, M. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.07.004 · Cited by 44 · cited 1×
“In persons with diabetes not specifically screendetected, intensive glucose control was associated with increased risk for severe hypoglycemia and serious nonhypoglycemia adverse events requiring medical intervention (Appendix Table 3) (59, 60, 63, 65).”
BackgroundNijpels, G., Boorsma, W., Dekker, J. M., Kostense, P. J., Bouter, L. M., & Heine, R. J. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.839 · Cited by 42 · cited 4×
“One trial found that, compared with placebo, acarbose was associated with greater risk for withdrawal because of adverse events (47).”
BackgroundInfluentialArmato, J., DeFronzo, R. A., Abdul-Ghani, M., & Ruby, R. (2012) · Endocrine Practice · doi:10.4158/ep11194.or · Cited by 35 · cited 1×
“Benefits of Treatment in IFG or IGT on the Delay or Prevention of Progression to Diabetes We identified 14 randomized, controlled trials (28, 29, 38–40, 45–47, 49, 83–89), 1 quasi-randomized trial (48), and 1 cohort study (90) on the effects of interventions for IFG or IGT on risk for progression to diabetes (Appendix…”
BackgroundPaddison, C. A. M., Eborall, H. C., French, D. P., Kinmonth, A. L., Prevost, A. T., Griffin, S. J., & Sutton, S. (2011) · British Journal of Health Psychology · doi:10.1348/135910710x495366 · Cited by 32 · cited 1×
“Studies lasting longer than the ADDITION and Ely trials (≥1 year) found no negative psychological effects associated with invitation to screening or notification of positive diabetes status (36, 37).”
BackgroundRahman, M., Simmons, R. K., Hennings, S. H., Wareham, N. J., & Griffin, S. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03570.x · Cited by 30 · cited 1×
“Studies lasting longer than the ADDITION and Ely trials (≥1 year) found no negative psychological effects associated with invitation to screening or notification of positive diabetes status (36, 37).”
BackgroundBlood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE
Poulter, N. R. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000354417.70192.be · Cited by 28 · cited 1×
“48]) mortality, whereas another (n = 11 140) (72, 73) found that, compared with placebo, the addition of an angiotensin-converting enzyme inhibitor plus a diuretic was associated with decreased risk for all-cause (RR, 0.”
BackgroundLu, Y., Lu, J., Wang, S., Li, C., Zheng, R.-P., Tian, H., & Wang, X. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0022-4 · Cited by 28 · cited 2×
“The studies assessed lifestyle interventions (6 studies) (38, 40, 84, 86–88), pharmacologic interventions (8 studies in 9 publications) (28, 29, 45–49, 89, 90), and multifactorial interventions (2 studies) (83, 85).”
Backgroundvan den Donk, M., Griffin, S. J., Stellato, R. K., Simmons, R. K., Sandbæk, A., Lauritzen, T., Khunti, K., Davies, M. J., Borch‐Johnsen, K., Wareham, N. J., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-3011-0 · Cited by 23 · cited 1×
“There was also no difference in self-reported measures of general and diabetes-specific quality of life (57).”
BackgroundSimmons, R. K., Sharp, S. J., Sandbæk, A., Borch‐Johnsen, K., Davies, M. J., Khunti, K., Lauritzen, T., Rutten, G. E. H. M., van den Donk, M., Wareham, N. J., et al. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03759.x · Cited by 22 · cited 2×
“Since the previous USPSTF review, there is now evidence from a large, good-quality trial that an intensive multifactorial intervention for screen-detected diabetes aimed at decreasing glucose and lipid levels and BP was not associated with a statistically significant reduction in risk for all-cause or cardiovascular m…”
BackgroundLindblad, U., Lindberg, G., Månsson, N. ‐., Ranstam, J., Tyrberg, M., Jansson, S. P. O., Lindwall, K., Svärdh, M., Kindmalm, L., & Melander, A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01331.x · Cited by 19 · cited 1×
“Other studies found that valsartan (29) and a combination of low-dose metformin and rosiglitazone (49), but not nateglinide (28) or glimepiride (89), was associated with reduced risk for progression to diabetes.”
BackgroundWu, H., Xu, M., Zou, D., Han, Q., & Hu, X. (2010) · PubMed · Cited by 14
Rasmussen, S. S., Glümer, C., Sandbæk, A., Lauritzen, T., & Borch‐Johnsen, K. (2008) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813430802264624 · Cited by 7 · cited 2×
“The studies assessed lifestyle interventions (6 studies) (38, 40, 84, 86–88), pharmacologic interventions (8 studies in 9 publications) (28, 29, 45–49, 89, 90), and multifactorial interventions (2 studies) (83, 85).”
Background
Research works printed but not linked: 4
- Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, 61, 918
- American Diabetes Association, 2015, Diabetes Care, 38, S1
- Van den Donk M, 2013, Diabetologia
- Wu H, 2010, Chin Med J (Engl), 123, 2908
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Manne-Goehler, J., Geldsetzer, P., Agoudavi, K., Andall-Brereton, G., Aryal, K. K., Bicaba, B. W., Bovet, P., Brian, G., Dorobantu, M., Gathecha, G., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002751 · Cited by 324
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force* (2015) · Annals of Internal Medicine · doi:10.7326/m15-2345 · Cited by 319
Hemmingsen, B., Gimenez-Perez, G., Mauricio, D., Roqué i Figuls, M., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003054.pub4 · Cited by 316
General health checks in adults for reducing morbidity and mortality from disease
Krogsbøll, L. T., Jørgensen, K. J., & Gøtzsche, P. C. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009009.pub3 · Cited by 202
Metadata
- Authors
- Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R.
- Affiliations
- Oregon Health & Science University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-06-02
- Volume
- 162
- Issue
- 11
- Pages
- 765-776
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2086557545
- Semantic Scholar
- 71271d7cc0522ec02fb4af61d3f48ff903988f34
- Cited by
- 134
- References
- 89
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 13 · 2022: 7 · 2021: 12 · 2020: 24 · 2019: 3 · 2018: 19 · 2017: 12 · 2016: 23 · 2015: 8
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (HHSA 290-2007-10057-I)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes screening, impaired fasting glucose, impaired glucose tolerance, screen-detected diabetes, progression to diabetes, lifestyle modification, tight glycemic control, intensive blood pressure control, cardiovascular mortality, all-cause mortality, USPSTF recommendations
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fasting, Humans, Life Style, Mass Screening, United States, Glucose Intolerance, Disease Progression, Risk Assessment, Early Diagnosis, Asymptomatic Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.